Related references
Note: Only part of the references are listed.NTRK-rearranged Cervical Sarcoma: Expanding the Clinicopathologic Spectrum
Anjelica Hodgson et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2021)
NTRK and other recently described kinase fusion positive uterine sarcomas: A review of a group of rare neoplasms
Sabrina Croce et al.
GENES CHROMOSOMES & CANCER (2021)
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
James P. Solomon et al.
MODERN PATHOLOGY (2020)
NTRKfusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma
Joseph T. Rabban et al.
HISTOPATHOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Spectrum ofTP53Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
Ulyana A. Boyarskikh et al.
FRONTIERS IN ONCOLOGY (2020)
Molecular characterization of cancers with NTRK gene fusions
Zoran Gatalica et al.
MODERN PATHOLOGY (2019)
Identifying patients with NTRK fusion cancer
J. P. Solomon et al.
ANNALS OF ONCOLOGY (2019)
Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors
Erin R. Rudzinski et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma
Sarah Chiang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting TRK family proteins in cancer
Yekaterina B. Khotskaya et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Jaclyn F. Hechtman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Share Paper
